Glyxambi
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
  • Users Online: 1059
  • Home
  • Print this page
  • Email this page

    Article Cited by others

SYMPOSIUM

Role of ranibizumab in management of macular degeneration

Singh Rishi P, Kaiser Peter K

Year : 2007| Volume: 55| Issue : 6 | Page no: 421-425

   This article has been cited by
 
1 Kinetics of retinal vaso-obliteration and neovascularisation in the oxygen-induced retinopathy (OIR) mouse model
Lange, C., Ehlken, C., Stahl, A., Martin, G., Hansen, L., Agostini, H.T.
Graefeæs Archive for Clinical and Experimental Ophthalmology. 2009; 247(9): 1205-1211
[Pubmed]  [Google Scholar]
2 Advance in the study of complication of anti-vascular endothelial growth factor following intravitreal injection
Meng, L., Chen, S.
Chinese Ophthalmic Research. 2009; 27(11): 1039-1043
[Pubmed]  [Google Scholar]
3 Indikationen für photodynamische Therapie mit Verteporfin im Zeitalter der intravitrealen Therapie – eine Übersicht
M. Stur
Spektrum der Augenheilkunde. 2008; 22(6): 340
[Pubmed]  [Google Scholar] [DOI]
4 Indikationen fur photodynamische Therapie mit Verteporfin im Zeitalter der intravitrealen Therapie--eine {\"U}bersicht
Stur, M.
Spektrum der Augenheilkunde. 2008; 22(6): 340-347
[Pubmed]  [Google Scholar]
5 Ranibizumab (Lucentis textregistered}) en degeneracion macular asociada a la edad (DMAE). Nuestra experiencia
Rodriguez, LJ and CABRERA, F. and Crespo, A. and CABRERA, B. and CASTELLANO, J. and JEREZ, E. and GARCIA, R. and CARDONA, P.
Archivos de la Sociedad Canaria de Oftalmologia. 2008; : 26
[Pubmed]  [Google Scholar]

 

Read this article